Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese approval for Diagnostic Hybrids' D3 Ultra respiratory virus test

This article was originally published in Clinica

Executive Summary

The Chinese state FDA (SFDA) has approved Diagnostic Hybrids' D3 Ultra DFA (direct fluorescence assay) respiratory virus screening and ID kit. The test can identify influenza A and B, parainfluenza 1, 2 and 3, respiratory syncytial virus and adenovirus. It can test patient specimens directly, providing results in 15 minutes, or cell culture, in combination with the firm's R-Mix and R-Mix Too Mixed FreshCells cell culture systems, giving results in 24-48 hours. Diagnostic Hybrids (Athens, Ohio), which became a subsidiary of Quidel after its acquisition in February, claims that the product is a market leader in the US clinical virology testing market. It was first cleared by the FDA in January 2006.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel